Status:
COMPLETED
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Lead Sponsor:
San Bernardino Urological Associates Medical Group Inc
Conditions:
Cancer of Prostate
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in adv...
Eligibility Criteria
Inclusion
- Patient with Advanced Ca, on stable dose of Lupron or Zoladex
- \-
Exclusion
- Previous exposure to Eligard.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00220194
Start Date
April 1 2003
End Date
June 1 2005
Last Update
October 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San bernardino Urological Associates Medical Group
San Bernardino, California, United States, 92404